Announcements

1 2 3 4 5 6 7 8 9 10

11

12 13

found Documents: 650

Announcements & Press Releases, Oncology / Immunology | 8 Apr 2013

Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting

1 item

London: Monday, 8 April 2013: Chi-Med today announces that data from the recently completed Phase I clinical trial of Fruquintinib (HMPL-013) and from preclinical studies of Volitinib (HMPL-504), two of the novel small molecule targeted anti-cancer d

Read More

View Announcement (PDF)

Announcements & Press Releases, Group | 26 Mar 2013

Final Results for the year ended 31 December 2012

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Feb 2013

Total Voting Rights

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 18 Feb 2013

Notice of Announcement of 2012 Final Results

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Jan 2013

TR-1: Notification of major interest in shares

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Dec 2012

Blocklisting Six Monthly Return

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Nov 2012

Chi-Med and Nestlé Health Science establish Joint Venture

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Nov 2012

Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib

1 item

London: Wednesday, 31 October 2012: Chi-Med announced that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309). This is the fourth oncology comp

Read More

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 8 Oct 2012

TR-1: Notification of major interest in shares

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Sep 2012

Total Voting Rights

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 13 Sep 2012

Director's Shareholding

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Aug 2012

Change of Nominated Adviser

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 31 Jul 2012

Interim Results for the Six Months Ended 30 June 2012

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 5 Jul 2012

Total Voting Rights

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2012

Announcement on Blocklisting Six Monthly Return

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Jun 2012

Notice of Announcement of 2012 Interim Results

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 14 Jun 2012

Exercise of Options

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Jun 2012

Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 May 2012

Director's Shareholding

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 11 May 2012

Results of Annual General Meeting

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 10 Apr 2012

2011 Annual Report and Notice of Annual General Meeting

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 20 Mar 2012

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Feb 2012

Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib

1 item

London: Wednesday, 22 February 2012: Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Volitinib (HMPL-504) in Australia. Volitinib

Read More

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 20 Feb 2012

Notice of Announcement of 2011 Final Results

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 14 Feb 2012

TR-1: Notification of major interests in shares

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 2 Feb 2012

Total Voting Rights

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 5 Jan 2012

TR-1: Notification of major interest in shares

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Dec 2011

Blocklisting Six Monthly Return

1 item

a111229

Announcements & Press Releases, Oncology / Immunology | 21 Dec 2011

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

1 item

London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen

Read More

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 12 Dec 2011

Chi-Med Loan Facility

1 item

a111212

Announcements & Press Releases, Oncology / Immunology | 4 Nov 2011

Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib

1 item

London, Friday, 4 November 2011: Hutchison MediPharma Limited (“HMP”), the drug R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Epitinib (HMPL-813). This is the third onc

Read More

a111104

Announcements & Press Releases, Regulatory Notice | 5 Sep 2011

TR-1: Notification of major interests in shares

1 item

a110905

Announcements & Press Releases, Group | 1 Aug 2011

Interim Results for the Six Months Ended 30 June 2011

1 item

a110801

Announcements & Press Releases, Other Ventures | 22 Jul 2011

China Healthcare Division expands OTC drug distribution and marketing operations

1 item

a110722

Announcements & Press Releases, Regulatory Notice | 5 Jul 2011

Notice of Announcement of 2011 Interim Results

1 item

a110705

Announcements & Press Releases, Regulatory Notice | 29 Jun 2011

Blocklisting Six Monthly Return

1 item

a110629

Announcements & Press Releases, Regulatory Notice | 13 May 2011

TR-1: Notification of major interests in shares

1 item

a110513

Announcements & Press Releases, Regulatory Notice | 9 May 2011

Results of Annual General Meeting

1 item

a110509a

Announcements & Press Releases, Regulatory Notice | 9 May 2011

TR-1: Notification of major interests in shares

1 item

a110509

Announcements & Press Releases, Regulatory Notice | 4 Apr 2011

2010 Annual Report and Notice of Annual General Meeting

1 item

a110404

Announcements & Press Releases, Regulatory Notice | 28 Mar 2011

Director's Shareholding

1 item

a110328

Announcements & Press Releases, Group | 9 Mar 2011

Final Results for the year ended 31 December 2010 Strong performance across all divisions.

1 item

a110309

Announcements & Press Releases, Regulatory Notice | 21 Feb 2011

Board Change

1 item

a110221

Announcements & Press Releases, Regulatory Notice | 15 Feb 2011

Appointment of UBS Limited as Joint Broker

1 item

a110215

Announcements & Press Releases, Oncology / Immunology | 1 Feb 2011

Fruquintinib receives SFDA IND approval Starts Phase I Clinical Trial for the treatment of cancer

1 item

London: Tuesday, 1 February 2011: Hutchison MediPharma Limited (“Hutchison MediPharma”), the drug R&D company majority owned by Chi-Med, today announces that it has started the first-in-human Phase I clinical trial of its anti-cancer drug can

Read More

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Jan 2011

Notice of Announcement of 2010 Final Results

1 item

a110131

Announcements & Press Releases, Regulatory Notice | 5 Jan 2011

Total Voting Rights

1 item

a110105

Announcements & Press Releases, Regulatory Notice | 29 Dec 2010

Blocklisting Six Monthly Return

1 item

a101229

Announcements & Press Releases, Oncology / Immunology | 21 Dec 2010

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline

1 item

a101221

Announcements & Press Releases, Other Ventures | 10 Dec 2010

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture

1 item

a101210

1 2 3 4 5 6 7 8 9 10

11